Testing the FastWire device for fully blocked leg arteries
Tests the FastWire System for crossing fully blocked arteries in adults' legs.
Key facts
- Who runs it
- Versono Medical Ltd
- Where
- Chattanooga, Cocoa, Davenport, Dearborn, Gray, and Wilmington, United StatesSee the 6 sites
- Trial code
- Registry title
- FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
- Status
- Recruiting
- People taking part
- 65 people, planned
- Started
- 5 Nov 2024
- Expected to end
- Nov 2026
- Type of study
- Interventional
- Treatments tested
- FastWire System - Peripheral
- Record updated
- 20 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a fully blocked leg artery (chronic total occlusion) who will have a procedure using the FastWire System to cross the blockage.
- Age
- 18 Years to 85 Years
- Sex
- All
- Disease stage
- Severe leg pain when walking (Rutherford category 3), or chronic limb-threatening ischaemia (Rutherford category 4 or 5). The blockage is new (de novo), 100% blocked, and below the start of the superficial femoral artery, above or below the knee. If there are several blockages, their total length is less than 40 cm (16 in). For blockages below the knee, at least one open run-off vessel (<50% stenosis) is needed.
- Earlier treatment
- No earlier bypass that includes the target vessel. No earlier angioplasty or stenting in the target blockage. No clot-dissolving (thrombolytic) therapy in the last two weeks.
Main reasons for not taking part
- Life expectancy of less than 12 months, or pregnant or breastfeeding.
- Heart attack or stroke in the 2 months before the procedure, or unstable heart disease.
- Bleeding or clotting problems, or platelet count < 50,000/μL.
- eGFR of less than 30 ml/min or creatine level >2.5mg/ml.
- Allergy to nickel, titanium or contrast medium, or active infection.
The registry criteria, word for word
Show all 29 criteriaShow less
Who cannot take part
- Myocardial infarction or stroke in two months prior to the index procedure
- Patients who have received any thrombolytic therapy in the last two weeks
- Subject participating in another study involving an investigational drug or device
- Patient has surgery or vascular intervention planned within 30 days of the index procedure
- Patient has had a previous peripheral bypass that includes the target vessel
- Patient has had a previous intervention in the target CTO (angioplasty, stenting) including previous attempt at time of index procedure
- Has perforation, dissection, or other injury of the access site or index vessel requiring stenting or surgical intervention prior to attempting crossing of the target lesion with the FastWire System
- Known, unstable coronary artery disease or other, uncontrolled comorbidity
- Evidence of active infection, including but not limited to the target limb
- History of severe allergy or contraindication, to contrast medium or other medications used during or after endovascular therapy
- Patient tests positive for coronavirus disease (COVID-2019), as per site standard practice
- Estimated Glomerular Filtration Rate (eGFR) of less than 30 ml/min or creatine level >2.5mg/ml
- Platelet count < 50,000/μL; Angiographic Exclusion Criteria; Unless otherwise specified, the Investigator performing the procedure bases angiographic exclusion on a visual determination of qualification imaging taken at the time of the procedure. Subject is excluded if ANY of the following angiographic exclusion criteria is met:
- Females who are pregnant or lactating (urine test for women of childbearing age)
- Subjects who meet any of the following criteria are not eligible for this clinical investigation:
- Life expectancy of less than 12 months
- Any known haemorrhagic or coagulation deficiency
- Known sensitivity to nickel, titanium, or their alloys
- Current use of cocaine or other substances of abuse
- For below-the-knee CTOs, a target limb without at least one patent (<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure
- Has an acute or sub-acute intraluminal thrombus within the target vessel
- Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac, or popliteal
Other criteria
- General Inclusion Criteria: Subjects who meet all the following criteria are eligible for this clinical investigation:
- The patient signed and dated an Informed Consent Form
- Aged between 18 years and 85 years (inclusive)
- Severe claudication assessed as Rutherford category 3 or CLTI assessed as Rutherford category 4 or 5 LEAD; Angiographic Inclusion Criteria; Unless otherwise specified, the Investigator performing the procedure bases angiographic inclusion on the visual determination of qualification imaging taken at the time of the procedure. Subject must meet ALL the following angiographic inclusion criteria:
- Angiographic confirmation at the time of the procedure of a de novo CTO below the origin of the superficial femoral artery (SFA) including above the knee or below the knee. (Note: Multilevel CTOs are included as long as the total length from the beginning of the most proximal total occlusion to the end of the most distal total occlusion is less than 40 cm.)
- 100% stenosis by a visual estimate of angiography at the time of procedure
- For below-the-knee CTOs, the target limb shall have at least one patent (<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at the time of the procedure
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
This trial is currently available in United States.
- Vascular Institute of ChattanoogaChattanooga, United StatesContact: Lacey WeeksTaking people
- Vascular & Embolization SpecialistsCocoa, United StatesContact: Brandon GalavizTaking people
- Vascular Institute of the MidwestDavenport, United StatesContact: Dr. Eric Dippel, M.D.Taking people
- Dearborn CardiologyDearborn, United StatesContact: Sam RengadeTaking people
- Cardiovascular Institute of the South-ASCGray, United StatesContact: Darla Patrick, RN, CCRCTaking people
- Endovascular ConsultantsWilmington, United StatesContact: Jas KaurTaking people
About the trial
What the trial wants to find out
This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs)
The group in the trial
- FastWire System - PeripheralTreatment being tested
This study is to assess the safety and efficacy of the FastWire System. It is intended to assess that the FastWire System can facilitate the intra-luminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions (CTOs).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Pivotal, Single-arm, Multi-centre, Prospective Clinical Investigation to Assess the Efficacy and Safety of the FastWire REvascularisation of Extremities, (For LOWer Limbs) (FREEFLOW).
- Plain-language title
- Testing the FastWire device for fully blocked leg arteriesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT06492733, who can take part
- Record updated
- 20 August 2026